Medical Research Council

Now, probably I was very young and naive.

The thing is, Particularly at such kind of institutions like the Medical Research Council, the Laboratory of Molecular Biology.

It's a very dedicated institution and like the history is up to 100 years, which is the kind of age of the molecular biology itself, probably older than that.

One thing I remember that I was waiting off the tea time, for example, because I was in the UK, they drink tea, not the coffee.

It's a principle that could be extended to learn how genes influence behaviour in humans and to understand neurological conditions where genes are known to play a big part.

So says research group co-leader Professor Greg Jeffries of the Medical Research Council.

There are patterns of behaviour that seem to have a strong genetic basis.

So, for example, schizophrenia.

And that's a tricky line.

And government obviously wants to encourage innovation, but then are you delivering net good? And then further down when it comes to health is, And this was something that Patrick Chinnery, who's exec chair of the MRC, said to me when I was writing the book.

And he said, well, what's the impact of all of this on the NHS? Because you may think you get benefit, but if you can't afford any of the follow-ups, you end up in the NHS.

And that then displaces care from somebody else.

That's all he got.

So there was also the first randomized clinical trial in the Medical Research Council study of streptomycin for pulmonary TB.

There were two patient groups.

streptomycin treatment group, and control treatment group.

Glasgow's subway stations benefiting from a hundred and fifty thousand pounds boost by Catherine Hunter.

A list of Glasgow's subway stations which have benefited from a hundred and fifty thousand pounds to improve accessibility has been released by the City Council.

Stations, including Queen Street train station and Partick Transport interchange hub, have been modernized for a third time since the subway, which is the third oldest in the world, opened in eighteen ninety-six.

Behind the scenes, SPT subway depot is also receiving an upgrade with an extension to the old stabling shed, new equipment to support and maintain new trains, and a brand-new control center.

It is also continuing to look at other options to improve access to its stations for all passengers.

This comes after Councillor Robert Mooney asked the Economy, Housing, Transport, and Regeneration Committee at its last meeting for a list of stations that had benefited from the scheme.

Members had been advised that SPT funding of a hundred and fifty thousand pounds had been secured to enhance pedestrian access and make the public transport network inclusive to all by removing barriers for disabled people, as well as those with mobility impairments.

The refurbished stations aim to offer a modern, welcoming environment for passengers, featuring tactile maps at key stations to assist those with visual impairments, and all ticket offices have induction loops for customers with hearing difficulties.

Firstly, some of the UK's biggest data centers are taking shape in Scotland with the government providing 80% debt guarantees.

Do the sums and the environmental concerns add up? And secondly, the Medical Research Council has announced a new AI-backed research facility in Cambridge that promises to help speed up the drug validation process.

but the big prizes may have already slipped away.

So, Matt, over to you for our first story this

This month, the government put 20 million into a research hub in Cambridge and called it transformative.

Merck's abandoned building was 50 times the size of the whole grant.

On August 12th, the Medical Research Council announced £20 million for something called the Preclinical Translational Models Hub.

It will sit at the Cambridge Stem Cell Institute and it is led by two professors there, Matthias Zilbauer and Bertie Gutgens.

But, but we have an absence of evidence of the impact of this.

And actually, Professor Patrick Chinnery, who was the exec chair of the Medical Research Council, the big sort of research body in the UK, funder in the UK, asked me a few times when I was writing the book, he said, "What's the impact of all of this, both on patients but our National Health Service? What, what's it doing to demand and, and, and the impact on demand?" And the answer is we don't know.

Although politicians in the UK are starting to take a bit of interest, I've had a few meetings with various MPs about this issue.

But going back to the transparency issue, there has to be transparency, but I think we need to be a bit health literate as well.